Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung

European Respiratory Journal

Volumn 47, Issue 5, 2016, Pages 1392-1401

  Locke, Landon W ^a   Myerburg, Michael M ^a   Weiner, Daniel J ^b   Markovetz, Matthew R ^c   Parker, Robert S ^a,c,d   Muthukrishnan, Ashok ^d   Weber, Lawrence ^d   Czachowski, Michael R ^b   Lacy, Ryan T ^c   Pilewski, Joseph M ^a,b   Corcoran, Timothy E ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c PA 15260   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETREOTIDE IN 111; TECHNETIUM SULFUR COLLOID TC 99M; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE; ARTICLE; BACTERIAL COLONIZATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; LUNG SCINTISCANNING; MALE; MEASUREMENT REPEATABILITY; MIDDLE AGED; MUCOCILIARY CLEARANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT PARAMETERS; SMALL MOLECULE ABSORPTION; SPUTUM CULTURE; YOUNG ADULT; AEROSOL; COMPLICATION; DISEASE EXACERBATION; INHALATIONAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; MICROBIOLOGY; MUCUS; PATHOLOGY; PATHOPHYSIOLOGY; RESPIRATORY SYSTEM; SCINTISCANNING;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUCOCILIARY CLEARANCE; MUCUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RESPIRATORY SYSTEM; YOUNG ADULT;

EID: 84969785021     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01880-2015     Document Type: Article

References (27)

1. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256: 774-779.
2. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95: 1005-1015.
3. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007; 261: 5-16.
4. Blouquit S, Regnier A, Dannhoffer L, et al. Ion and fluid transport properties of small airways in cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 299-305.
5. Rowe SM, Heltshe SL, Gonska T, et al. clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; 190: 175-184.
6. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241-250.
7. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: A pilot study. Eur Respir J 1999; 14: 678-685.
8. Bennett WD, Laube BL, Corcoran T, et al. Multisite comparison of mucociliary and cough clearance measures using standardized methods. J Aerosol Med Pulm Drug Deliv 2013; 26: 157-164.
9. Donaldson SH, Corcoran TE, Laube BL, et al. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc 2007; 4: 399-405.
10. Corcoran TE, Thomas KM, Myerburg MM, et al. Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway. Eur Respir J 2010; 35: 781-786.
11. Corcoran TE, Thomas KM, Brown S, et al. Liquid hyper-absorption as a cause of increased DTPA clearance in the cystic fibrosis airway. EJNMMI Res 2013; 3: 14.
12. Locke LW, Myerburg MM, Markovetz MR, et al. Quantitative imaging of airway liquid absorption in cystic fibrosis. Eur Respir J 2014; 44: 675-684.
13. Markovetz MR, Corcoran TE, Locke LW, et al. A physiologically-motivated compartment-based model of the effect of inhaled hypertonic saline on mucociliary clearance and liquid transport in cystic fibrosis. PloS One 2014; 9: e111972.
14. Laube BL, Sharpless G, Benson J, et al. Mucus removal is impaired in children with cystic fibrosis who have been infected by Pseudomonas aeruginosa. J Pediatr 2014; 164: 839-845.
15. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11: 116-128.
16. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987; 136: 1445-1449.
17. Regnis JA, Robinson M, Bailey DL, et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994; 150: 66-71.
18. Robinson M, Eberl S, Tomlinson C, et al. Regional mucociliary clearance in patients with cystic fibrosis. J Aerosol Med 2000; 13: 73-86.
19. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52: 900-903.
20. Wilson R, Roberts D, Cole P. Effect of bacterial products on human ciliary function in vitro. Thorax 1985; 40: 125-131.
21. Mallants R, Jorissen M, Augustijns P. Beneficial effect of antibiotics on ciliary beat frequency of human nasal epithelial cells exposed to bacterial toxins. J Pharm Pharmacol 2008; 60: 437-443.
22. Rada B, Leto TL. Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas aeruginosa airway infections. Trends Microbiol 2013; 21: 73-81.
23. Read RC, Roberts P, Munro N, et al. Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating. J Appl Physiol 1992; 72: 2271-2277.
24. Henke MO, John G, Germann M, et al. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med 2007; 175: 816-821.
25. Hao Y, Kuang Z, Walling BE, et al. Pseudomonas aeruginosa pyocyanin causes airway goblet cell hyperplasia and metaplasia and mucus hypersecretion by inactivating the transcriptional factor FoxA2. Cell Microbiol 2012; 14: 401-415.
26. Petersen NT, Høiby N, Mordhorst CH, et al. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand 1981; 70: 623-628.
27. Collinson J, Nicholson KG, Cancio E, et al. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 1996; 51: 1115-1122.